The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Abstract
Purpose: The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor. We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment. Patients and Methods: Salvage treatment consisted of two cycles of high-dose cytarabine and etoposide (CYVE). Intensive chemotherapy combined thiotepa, busulfan, and cyclophosphamide. Forty-three patients (median age, 52 years; range, 23 to 65 years) were included, with relapse (n = 22), refractory disease (n = 17), or a partial response to first-line treatment (n = 4). The response to CYVE was not assessable in three cases because of treatment-related death. Twenty patients (47%) were chemosensitive to CYVE: 15 of them proceeded to IC + HCR. IC + HCR was also administered to 12 patients who did not respond to CYVE. All but one of the 27 patients who underwent IC + HCR entered complete remission. Results: With a median follow-up of 36 months, the median overall survival was 18.3 months in the overall population, and 58.6 months among patients who completed IC + HCR. The respective median progression-free survival (PFS) times after IC + HCR were 11.6 and 41.1 months. The 2-year overall survival probability was 45% in the whole population and 69% among the 27 patients who received IC + HCR. The 2-year PFS probability was 43% among all the patients and 58% in the IC + HCR subpopulation. Conclusion: IC + HCR is an effective treatment for refractory and recurrent PCNSL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.-Y., Harousseau, J.-L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332305 · Cited by 2,439
Self-citationAbrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Self-citationChemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Self-citationSoussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V., Azar, N., Belanger, C., Achour, E., Ribrag, V., Gerber, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.742 · Cited by 322
Self-citationIllerhaus, G., Marks, R., Ihorst, G., Guttenberger, R., Ostertag, C., Derigs, G., Frickhofen, N., Feuerhake, F., Volk, B., & Finke, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2117 · Cited by 297
Nguyen, P. L., Chakravarti, A., Finkelstein, D. M., Hochberg, F. H., Batchelor, T. T., & Loeffler, J. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.161 · Cited by 236
Jahnke, K., Thiel, E., Martus, P., Herrlinger, U., Weller, M., Fischer, L., Korfel, A., & on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG) (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9165-6 · Cited by 201
Correa, D. D., Maron, L., Harder, H., Klein, M., Armstrong, C. L., Calabrese, P., Bromberg, J. E. C., Abrey, L. E., Batchelor, T. T., & Schiff, D. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl464 · Cited by 186
Heideman, R. L., Cole, D. E., Balis, F. M., Sato, J., Reaman, G. H., Packer, R. J., Singher, L. J., Ettinger, L. J., Gillespie, A., & Sam, J. (1989) · PubMed · Cited by 142
Reni, M., Mason, W. P., Zaja, F. F., Perry, J., Franceschi, E., Bernardi, D., Dell’Oro, S., Stelitano, C. C., Candela, M., Abbadessa, A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.008 · Cited by 120
Cited by
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Self-citationNayak, L., Iwamoto, F. M., LaCasce, A., Mukundan, S., Roemer, M. G. M., Chapuy, B., Armand, P., Rodig, S. J., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-01-764209 · Cited by 453
Hoang-Xuan, K., Bessell, E., Bromberg, J., Hottinger, A. F., Preusser, M., Rudà, R., Schlegel, U., Siegal, T., Soussain, C., Abacioglu, U., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00076-5 · Cited by 411
Self-citationHouillier, C., Taillandier, L., Dureau, S., Lamy, T., Laadhari, M., Chinot, O., Moluçon-Chabrot, C., Soubeyran, P., Gressin, R., Choquet, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00306 · Cited by 287
Self-citation
Metadata
- Authors
- Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A.-L., Gisselbrecht, C., Jaccard, A., Omuro, A., Sanson, M., Janvier, M., Kolb, B., Zini, J.-M., & Leblond, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15
- Pages
- 2512-2518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120766517
- Cited by
- 324
- References
- 12
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. https://app.cochat.ai/papers/10.1200/jco.2007.13.5533
- The paper
- Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A.-L., Gisselbrecht, C., Jaccard, A., Omuro, A., Sanson, M., Janvier, M., Kolb, B., Zini, J.-M., & Leblond, V. (2008). Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.13.5533
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
